{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:14:45Z","timestamp":1788502485073,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-05207-4","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T01:42:23Z","timestamp":1786066943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world efficacy and safety of sofosbuvir\/velpatasvir\/voxilaprevir in treatment-naive and treatment-experienced chronic hepatitis c patients: a single-center study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8674-2141","authenticated-orcid":false,"given":"Alper","family":"Tahmaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7966-3234","authenticated-orcid":false,"given":"\u00dclk\u00fc","family":"\u00dcser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1147-0985","authenticated-orcid":false,"given":"Merve Safa","family":"Ke\u00e7e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"5207_CR1","unstructured":"World Health Organization, Hepatitis C. World Health Organization: Geneva, Switzerland. [cited 2026 Apr 25]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c. Accessed 25 Apr 2026."},{"key":"5207_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.54394\/CJQU6666","volume-title":"Global hepatitis report 2024: action for access in low- and middle-income countries","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva: World Health Organization;Licence: CC BY-NC-SA 3.0 IGO. Isbn 978-92-4-009167-2. cited 2026 Apr 25. 2024:1\u2013242. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b.\u00a0 Accessed 25 Apr 2026."},{"key":"5207_CR3","unstructured":"World Health Organization. Implementing the global health sector strategies on HIV, viral hepatitis and sexually transmitted infections, 2022\u20132030: report on progress and gaps 2024. World Health Organization; 2024. ISBN: 978-92-4-009492-5. https:\/\/www.who.int\/publications\/i\/item\/9789240094925"},{"key":"5207_CR4","unstructured":"New Molecular Entity Application (NME) Approvals. Cited 2026 Apr 25. https:\/\/www.fda.gov\/media\/110746\/download. Accessed 25 Apr 2026."},{"key":"5207_CR5","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"J-M Pawlotsky","year":"2020","unstructured":"Pawlotsky J-M, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL recommendations on treatment of hepatitis C: final update of the series\u2606. J Hepatol Elsevier. 2020;73:1170\u2013218.","journal-title":"J Hepatol Elsevier"},{"key":"5207_CR6","doi-asserted-by":"publisher","unstructured":"Bhattacharya D, Aronsohn A, Price J, Lo Re V, Heald J, Demisashi G et al. Infectious Diseases Society of America HCV Guidance Panel. Hepatitis C guidance 2023 update: American Association for the Study of Liver Diseases\u2013Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus. Clin Infect Dis [Internet]. Clin Infect Dis. Cited 2026 Apr 25. 2023;1\u201318. https:\/\/doi.org\/10.1093\/CID\/CIAD319.","DOI":"10.1093\/CID\/CIAD319"},{"key":"5207_CR7","unstructured":"Sosyal G\u00fcvenlik Kurumu Sa\u011fl\u0131k Uygulama Tebli\u011fi. 01\/06\/2022 tarihli ve 31853 say\u0131l\u0131 Resmi Gazete\u2019de Yay\u0131mlanan Sosyal G\u00fcvenlik Kurumu Sa\u011fl\u0131k Uygulama Tebli\u011finde De\u011fi\u015fiklik Yap\u0131lmas\u0131na Dair Tebli\u011f, Ankara, T\u00dcRK\u0130YE. cited 2026 Apr 25. https:\/\/www.sgk.gov.tr\/Duyuru\/Detay\/01062022-tarihli-ve-31853-sayili-Resmi-Gazetede-Yayimlanan-Sosyal-Guvenlik-Kurumu-Saglik-Uygulama-Tebliginde-Degisiklik-Yapilmasina-Dair-Teblig-2022-06-02-04-44-36. Accessed 25 Apr 2026."},{"key":"5207_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4274\/VHD.GALENOS.2023.2023-5-2","volume":"29","author":"TD \u00c7ak\u0131rca","year":"2023","unstructured":"\u00c7ak\u0131rca TD, Yamazhan T, Y\u00fcksekkaya E, Akg\u00fcl F, Kurtaran B, Kara\u015fahin \u00d6, et al. Sofosbuvir\/Velpatasvir\/Voxilaprevir Experience in Treatment-Naive Chronic Hepatitis C Patients: Preliminary Findings of Real World Data. Viral Hepat J Viral Hepat J. 2023;29:58\u201363. https:\/\/doi.org\/10.4274\/VHD.GALENOS.2023.2023-5-2.","journal-title":"Viral Hepat J Viral Hepat J"},{"key":"5207_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/v17070931","volume":"17","author":"UD Binay","year":"2025","unstructured":"Binay UD, Karake\u00e7ili F, Aygen B, K\u0131l\u0131n\u00e7 Toker A, \u00c7elik \u0130, Demirt\u00fcrk N, et al. Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir\/Velpatasvir\/Voxilaprevir: A Multicenter Real-World Experience from T\u00fcrkiye. Viruses. 2025;17:1\u201314. https:\/\/doi.org\/10.3390\/v17070931.","journal-title":"Viruses"},{"key":"5207_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1053\/J.GASTRO.2017.03.047","volume":"153","author":"IM Jacobson","year":"2017","unstructured":"Jacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, Nahass RG, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterol Elsevier. 2017;153:113\u201322. https:\/\/doi.org\/10.1053\/J.GASTRO.2017.03.047.","journal-title":"Gastroenterol Elsevier"},{"key":"5207_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/apt.18020","volume":"60","author":"JC Ruiz-Cobo","year":"2024","unstructured":"Ruiz-Cobo JC, Llaneras J, Forns X, Gallego Moya A, Conde Amiel I, Arencibia A, et al. Real\u2010life effectiveness of sofosbuvir\/velpatasvir\/voxilaprevir in hepatitis C patients previously treated with sofosbuvir\/velpatasvir or glecaprevir\/pibrentasvir. Aliment Pharmacol Ther Wiley Online Libr. 2024;60:201\u201311.","journal-title":"Aliment Pharmacol Ther Wiley Online Libr"},{"key":"5207_CR12","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3904\/kjim.2022.252","volume":"38","author":"J Heo","year":"2023","unstructured":"Heo J, Kim YJ, Lee SW, Lee Y-J, Yoon KT, Byun KS, et al. Efficacy and safety of sofosbuvir\u2013velpatasvir and sofosbuvir\u2013velpatasvir\u2013voxilaprevir for hepatitis C in Korea: a Phase 3b study. Korean J Intern Med. 2023;38:504.","journal-title":"Korean J Intern Med"},{"key":"5207_CR13","first-page":"518","volume":"38","author":"C Wai","year":"2003","unstructured":"Wai C, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. Wiley Online Libr. 2003;38:518\u201326.","journal-title":"Wiley Online Libr"},{"key":"5207_CR14","doi-asserted-by":"publisher","unstructured":"Liver EA for the S of the, Berzigotti A, Tsochatzis E, Boursier J, Castera L, Cazzagon N et al EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u2013 2021 update. J Hepatol. 2021;75:659\u201389. https:\/\/doi.org\/10.1016\/j.jhep.2021.05.025.","DOI":"10.1016\/j.jhep.2021.05.025"},{"key":"5207_CR15","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S1665-2681(19)31836-8","volume":"7","author":"A Loaeza-del-Castillo","year":"2008","unstructured":"Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-C\u00e1rdenas E, S\u00e1nchez-\u00c1vila F, Vargas-Vor\u00e1ckov\u00e1 F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol. 2008;7:350\u20137.","journal-title":"Ann Hepatol"},{"key":"5207_CR16","unstructured":"US Food and Drug Administration Approves Gileads Vosevi. SofosbuvirVelpatasvirVoxilaprevir for Re Treatment of Adults with Chronic Hepatitis C Virus. Cited 2026 May 1. https:\/\/www.gilead.com\/news\/news-details\/2017\/us-food-and-drug-administration-approves-gileads-vosevi-sofosbuvirvelpatasvirvoxilaprevir-for-re-treatment-of-adults-with-chronic-hepatitis-c-virus. Accessed 1 May 2026."},{"key":"5207_CR17","unstructured":"Phase A. 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir\/Velpatasvir\/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir\/Velpatasvir for 12 Weeks in Subjects With Chronic Genotype 3 HCV Infection and Cirrhosis. 2015. https:\/\/clinicaltrials.gov\/study\/NCT02639338."},{"key":"5207_CR18","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.jhep.2019.07.020","volume":"71","author":"E Degasperi","year":"2019","unstructured":"Degasperi E, Spinetti A, Lombardi A, Landonio S, Rossi MC, Pasulo L, et al. Real-life effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in hepatitis C patients with previous DAA failure. J Hepatol [Internet] Elsevier B V. 2019;71:1106\u201315. https:\/\/doi.org\/10.1016\/j.jhep.2019.07.020. [cited 2026 May 2];.","journal-title":"J Hepatol [Internet] Elsevier B V"},{"key":"5207_CR19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/S12072-022-10475-9","volume":"17","author":"CH Liu","year":"2023","unstructured":"Liu CH, Peng CY, Liu CJ, Chen CY, Lo CC, Tseng KC, et al Sofosbuvir\/velpatasvir\/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan. Hepatol Int. 2023;17:291\u2013302. . 2023 172. Springer;[cited 2026 May 2]. https:\/\/doi.org\/10.1007\/S12072-022-10475-9.","journal-title":"Hepatol Int"},{"key":"5207_CR20","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/S40121-022-00666-0","volume":"11","author":"J Xie","year":"2022","unstructured":"Xie J, Xu B, Wei L, Huang C, Liu W Effectiveness and Safety of Sofosbuvir\/Velpatasvir\/Voxilaprevir as a Hepatitis C Virus Infection Salvage Therapy in the Real World: A Systematic Review and Meta-analysis. Infect Dis Ther [Internet]. Infect Dis Ther. Cited 2026 May 2. 2022;11:1661\u201382. https:\/\/doi.org\/10.1007\/S40121-022-00666-0.","journal-title":"Infect Dis Ther Cited 2026 May 2"},{"key":"5207_CR21","doi-asserted-by":"publisher","unstructured":"Omar WH, Mostafa M, Mohammed SA, Allawy MA, Salama BM. Characterization of Hepatitis C Patients Received Direct Acting Antiviral Therapy in Suez Governorate, Egypt. Single Center Experience. Egypt J Med Microbiol. Egyptian Society for Medical Microbiology (ESMM); 2026. https:\/\/doi.org\/10.21608\/ejmm.2026.457307.2094","DOI":"10.21608\/ejmm.2026.457307.2094"},{"key":"5207_CR22","doi-asserted-by":"publisher","unstructured":"Azeem HA, Alkabeer AM, Mohammed AS, Hussein AA. Study of hepatitis B virus infection, reactivation among patients with chronic hepatitis C infection treated by direct antiviral agents (DAAs). Egypt Liver J 2021 111 . SpringerOpen; cited 2026 May 3. 2021;11:53\/ https:\/\/doi.org\/10.1186\/S43066-021-00121-8.","DOI":"10.1186\/S43066-021-00121-8"},{"key":"5207_CR23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/LIV.14186;JOURNAL:JOURNAL:16000676;WGROUP:STRING:PUBLICATION","volume-title":"Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs","author":"F Tacke","year":"2020","unstructured":"Tacke F, Boeker KHW, Klinker H, Heyne R, Buggisch P, Pathil A, et al Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs. Liver Int. Blackwell Publishing Ltd;. Cited 2026 May 3. 2020;40: 239\u201348. https:\/\/doi.org\/10.1111\/LIV.14186;JOURNAL:JOURNAL:16000676;WGROUP:STRING:PUBLICATION."},{"key":"5207_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.21608\/djs.2023.205149.1106","volume":"46","author":"HS Kamal","year":"2023","unstructured":"Kamal HS, Atta NA, Ismael NR, Aldash HA, Gomaa AA. Biochemical study on the response to HCV therapy (Velpatasvir containing regimen),(vosevi) among adult patients\u2019 non-responders to treatment in Fayoum Egypt. Delta J Sci Tanta Univ Fac Sci. 2023;46:123\u201334.","journal-title":"Delta J Sci Tanta Univ Fac Sci"},{"key":"5207_CR25","doi-asserted-by":"publisher","unstructured":"Hsu WF, Lai HC, Su WP, Lin CH, Chuang PH, Chen SH et al. Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents. BMC Gastroenterol 2019 191. BioMed Central; cited 2026 May 3. 2019;19:63. https:\/\/doi.org\/10.1186\/S12876-019-0973-5.","DOI":"10.1186\/S12876-019-0973-5"},{"key":"5207_CR26","doi-asserted-by":"publisher","unstructured":"Huynh T, Zhang J, Hu KQ Hepatitis C Virus Clearance by Direct-acting Antiviral Results in Rapid Resolution of Hepatocytic Injury as Indicated by Both Alanine Aminotransferase and Aspartate Aminotransferase Normalization. J Clin Transl Hepatol. Xia and He Publishing Inc.;, Cited. 2026 May 3. 2018;6:258. https:\/\/doi.org\/10.14218\/JCTH.2018.00014.","DOI":"10.14218\/JCTH.2018.00014"},{"key":"5207_CR27","first-page":"e50","volume":"64","author":"HI Shousha","year":"2022","unstructured":"Shousha HI, Abdelghafour R, Dabees H, AbdelRazek W, Said M. Three regimens for re-treatment failure of Sofosbuvir-based therapy for chronic hepatitis-C genotype-4: a cohort study. Rev Inst Med Trop Sao Paulo SciELO Brasil. 2022;64:e50.","journal-title":"Rev Inst Med Trop Sao Paulo SciELO Brasil"},{"key":"5207_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.21608\/mjvh.2020.80655","volume":"4","author":"E Dina","year":"2020","unstructured":"Dina E, Nasser M, Sarah E, Mahmoud A, Islam M, Waleed E, et al. Pretreatment serum alpha fetoprotein and its relation to sustained virologic response in patients with chronic HCV infection treated with direct-acting antiviral therapy. Med J Viral Hepat Egypt Liver Res Inst Hosp (ELRISH). 2020;4:69\u201373.","journal-title":"Med J Viral Hepat Egypt Liver Res Inst Hosp (ELRISH)"},{"key":"5207_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-019-0973-5","volume":"19","author":"WF Hsu","year":"2019","unstructured":"Hsu WF, Lai HC, Su WP, Lin CH, Chuang PH, Chen SH, et al. Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents. BMC Gastroenterol BMC Gastroenterol. 2019;19:1\u20139. https:\/\/doi.org\/10.1186\/s12876-019-0973-5.","journal-title":"BMC Gastroenterol BMC Gastroenterol"},{"key":"5207_CR30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.22543\/7674.62.p210215","volume":"6","author":"O Orasan","year":"2019","unstructured":"Orasan O, Ciulei G, Coste S, Cibu B, Taut A, Tarmure S, et al. The evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents \u2013 A review of the literature. J Mind Med Sci. 2019;6:210\u20135. https:\/\/doi.org\/10.22543\/7674.62.p210215.","journal-title":"J Mind Med Sci"},{"key":"5207_CR31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.14744\/hf.2020.2020.0002","volume":"1","author":"AG Tufan","year":"2020","unstructured":"Tufan AG, Hakim GD, Akar H, Akarsu M. Evaluation of fibrosis in chronic hepatitis C patients treated with direct-acting antivirals. Hepatol Forum. 2020;1:53\u20138. https:\/\/doi.org\/10.14744\/hf.2020.2020.0002.","journal-title":"Hepatol Forum"},{"key":"5207_CR32","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1002\/hep4.2098","volume":"6","author":"T Huynh","year":"2022","unstructured":"Huynh T, Ma S, Hu KQ. HCV direct acting antiviral treatment leads to highly durable rates of ALT and AST lower than 30\/19 criteria and improved APRI and FIB-4 scores. Hepatol Commun. 2022;6:3496\u2013504. https:\/\/doi.org\/10.1002\/hep4.2098.","journal-title":"Hepatol Commun"},{"key":"5207_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/v17070949","volume":"17","author":"JH Yoon","year":"2025","unstructured":"Yoon JH, Lee CH, Jo HG, Cho JY, Kim JD, Kim JW, et al. Real-World Treatment Efficacy and Safety Profile of Sofosbuvir- and Velpatasvir-Based HCV Treatment in South Korea: Multicenter Prospective Study. Viruses. 2025;17:1\u201312. https:\/\/doi.org\/10.3390\/v17070949.","journal-title":"Viruses"},{"key":"5207_CR34","doi-asserted-by":"publisher","first-page":"437","DOI":"10.15403\/jgld-4472","volume":"31","author":"L Gheorghe","year":"2022","unstructured":"Gheorghe L, Preda CM, Trifan A, Manuc M, Stanciu C, Istratescu D, et al. Real World Efficacy and Safety of Sofosbuvir\u2009+\u2009Velpatasvir\u2009+\u2009Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy. J Gastrointest Liver Dis. 2022;31:437\u201343. https:\/\/doi.org\/10.15403\/jgld-4472.","journal-title":"J Gastrointest Liver Dis"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-05207-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05207-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05207-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:11:27Z","timestamp":1788502287000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-05207-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5207"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-05207-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9762145\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was reviewed and approved by the Clinical Research Ethics Committee of Antalya Training and Research Hospital (Decision no.: 9\/27, Date: May 7, 2026). All procedures performed in this study involving human participants were conducted in accordance with the ethical standards of the institutional and national research committee, as well as with the 1964 Helsinki declaration and its later amendments. Given the retrospective observational longitudinal cohort design of the study utilizing anonymized historical clinical data, the requirement for written informed consent was waived by the Clinical Research Ethics Committee of Antalya Training and Research Hospital.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. The manuscript does not contain any potentially identifying personal information, individual clinical details, or recognizable images of the patients.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"543"}}